Stephanie Monaghan O Brien Net Worth

The estimated Net Worth of Stephanie Monaghan O Brien is at least $167 millier dollars as of 20 April 2015. Stephanie Brien owns over 3,400 units of Aduro BioTech stock worth over $167,450 and over the last 10 years Stephanie sold ADRO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stephanie Brien ADRO stock SEC Form 4 insiders trading

Stephanie has made over 1 trades of the Aduro BioTech stock since 2015, according to the Form 4 filled with the SEC. Most recently Stephanie bought 3,400 units of ADRO stock worth $57,800 on 20 April 2015.

The largest trade Stephanie's ever made was buying 3,400 units of Aduro BioTech stock on 20 April 2015 worth over $57,800. On average, Stephanie trades about 425 units every 0 days since 2015. As of 20 April 2015 Stephanie still owns at least 1,700 units of Aduro BioTech stock.

You can see the complete history of Stephanie Brien stock trades at the bottom of the page.

What's Stephanie Brien's mailing address?

Stephanie's mailing address filed with the SEC is C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY, CA, 94710.

Insiders trading at Aduro BioTech

Over the last 10 years, insiders at Aduro BioTech have traded over $5,295,750 worth of Aduro BioTech stock and bought 614,134 units worth $10,440,278 . The most active insiders traders include William Mariner Greenman, Stephen T Isaacs et Thomas W. Dubensky. On average, Aduro BioTech executives and independent directors trade stock every 11 days with the average trade being worth of $2,189,064. The most recent stock trade was executed by Stephen T Isaacs on 15 September 2020, trading 32,481 units of ADRO stock currently worth $77,630.

What does Aduro BioTech do?

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Complete history of Stephanie Brien stock trades at Aduro BioTech

Aduro BioTech executives and stock owners

Aduro BioTech executives and other stock owners filed with the SEC include:

• William Greenman,
  Independent Director
• Ross Haghighat,
  Independent Director
• Eric Bjerkholt,
  Chief Financial Officer
• Noopur Liffick,
  IR Contact Officer
• Dolca Thomas,
  Director
• Michelle Griffin,
  Director
• Jerel Davis,
  Director
• Srinivas Akkaraju,
  Director
• Alan Glicklich,
  Chief Medical Officer
• Tom Frohlich,
  Chief Business Officer
• Eric Dobmeier,
  President, Chief Executive Officer, Director
• Thomas W. Dubensky,
  Chief Scientific Officer
• Gregory W Schafer,
  Chief Operating Officer
• Natalie Sacks,
  Chief Medical Officer
• Frank Mccormick,
  Director
• Gerald Chan,
  Director
• Stephen T Isaacs,
  President and CEO
• Stephanie Monaghan O Brien,
  Director
• Stephen A Sherwin,
  Director
• Dirk G. Brockstedt,
  Sr. VP of Research and Dev.
• Frank Karbe,
  Director
• Elsas Andrea Van,
  Chief Scientific Officer
• David Henry Mack,
  Director
• Celeste Ferber,
  SVP, GC and Secretary
• Dimitry Sa Nuyten,
  Chief Medical Officer
• Jennifer Lew,
  Sr. Vice President of Finance
• Venture (Vi) Investments Lt...,
  10% owner
• John E. And Lois A. Rogers,
  10% owner
• Keen Ltd Ultimate,
  10% owner
• Blaine Templeman,
  Chief Legal Officer
• James H Welch,
  See Remarks
• William G Kachioff,
  Interim CFO